Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
In a recent cardiovascular trial, semaglutide demonstrated a reduction in albuminuria, a marker of kidney damage, and slowed the decline in kidney function
Sema is part of a class of medications called GLP-1 receptor agonists, or glucagon-like peptide-1 receptor agonists
IV infusion: for higher doses, given over 30 minutes to several hours
Atherosclerosis as pathogenetic substrate for Sars-Cov 2 cytokine storm
Longer-term data (72104 weeks across trials) support continued efficacy and a safety profile consistent with earlier phases
US$ 28.57
US$ 24.95
US$ 27.96
